Peripheral nerve involvement in primary systemic AL amyloidosis: A clinical and electrophysiological study

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 604-610

  Matsuda, M ^a   Gono, T ^a   Morita, H ^a   Katoh, N ^a   Kodaira, M ^a   Ikeda, S ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; Autonomic nerve dysfunction; Carpal tunnel syndrome; Polyneuropathy

Indexed keywords

BENCE JONES PROTEIN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; M PROTEIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTONOMIC DYSFUNCTION; BONE MARROW BIOPSY; CARPAL TUNNEL SYNDROME; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LEG DISEASE; LEG PAIN; MALE; MEDIAN NERVE; MOTOR DYSFUNCTION; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; POLYNEUROPATHY; PRIMARY SYSTEMIC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSORY DYSFUNCTION; STEM CELL TRANSPLANTATION; TIBIAL NERVE;

ADULT; AGED; AMYLOIDOSIS; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES;

EID: 79952721367     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03215.x     Document Type: Article

References (22)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
2. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801-2806.
3. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
4. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid: J Protein Folding Disord 2004; 11: 245-256.
5. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.
6. Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979; 6: 1-7.
7. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998; 104: 232-237.
8. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319-328.
9. Hoshii Y, Kiyama M, Cui D, Kawano H, Ishihara T. Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region. Pathol Int 2006; 56: 324-330.
10. Yoshida T, Matsuda M, Katoh N, et al. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Intern Med 2008; 47: 1783-1790.
11. Katoh N, Matsuda M, Yoshida T, et al. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. Muscle Nerve 2010; 41: 138-143.
12. Matsuda M, Gono T, Katoh N, et al. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. Intern Med 2008; 47: 543-549.
13. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
14. Kyle RA, Dyck PJ. Amyloidosis and neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy, 3rd edn. Philadelphia: W.B. Saunders, 1993: 1294-1309.
15. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropoathy in Japan. Clinical and genetic heterogeneity. Neurology 2002; 58: 1001-1007.
16. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid: J Protein Folding Disord 2003; 10: 160-184.
17. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411-423.
18. Koike H, Misu K, Ikeda S, et al. Type 1 (transthyretin Met30) familial amyloid polyneuropathy in Japan. Early- vs late-onset form. Arch Neurol 2002; 59: 1771-1776.
19. Koike H, Morozumi S, Kawagashira Y, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid: J Protein Folding Disord 2009; 16: 142-148.
20. Tojo K, Tsuchiya-Suzuki A, Sekijima Y, Morita H, Sumita N, Ikeda S. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Amyloid: J Protein Folding Disord 2010; 17: 32-35.
21. Ando Y, Araki S, Shimoda O, Kano T. Role of autonomic nerve functions in patients with familial amyloidotic polyneuropathy as analyzed by laser doppler flowmetry, capsule hydrograph, and cardiographic R-R interval. Muscle Nerve 1991; 15: 507-512.
22. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid: J Protein Folding Disord 2007; 14: 261-269.